$882 Million is the total value of Aquilo Capital Management, LLC's 14 reported holdings in Q4 2021. The portfolio turnover from Q3 2021 to Q4 2021 was 28.6% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SPY | New | SPDR S&P 500 ETF TR TRput | $474,960,000 | – | 1,000,000 | +100.0% | 53.87% | – |
| SPRO | Buy | SPERO THERAPEUTICS INC | $79,477,000 | -5.4% | 4,964,181 | +8.8% | 9.01% | -40.9% |
| BPMC | Buy | BLUEPRINT MEDICINES CORP | $69,144,000 | +28.9% | 645,539 | +23.7% | 7.84% | -19.5% |
| ARWR | Buy | ARROWHEAD PHARMACEUTICALS IN | $46,438,000 | +40.9% | 700,426 | +32.7% | 5.27% | -12.0% |
| ARVN | Buy | ARVINAS INC | $46,282,000 | +58.8% | 563,451 | +58.8% | 5.25% | -0.9% |
| RGNX | Buy | REGENXBIO INC | $33,145,000 | -5.8% | 1,013,596 | +20.8% | 3.76% | -41.2% |
| FDMT | Buy | 4D MOLECULAR THERAPEUTICS IN | $33,128,000 | +11.7% | 1,509,944 | +37.3% | 3.76% | -30.3% |
| MRUS | New | MERUS N V | $28,509,000 | – | 896,502 | +100.0% | 3.23% | – |
| AMYT | Buy | AMRYT PHARMA PLCsponsored ads | $17,712,000 | +5.8% | 1,640,000 | +18.0% | 2.01% | -33.9% |
| QURE | Sell | UNIQURE NV | $14,025,000 | -66.8% | 676,206 | -48.8% | 1.59% | -79.3% |
| MGTA | MAGENTA THERAPEUTICS INC | $13,977,000 | -39.1% | 3,155,082 | 0.0% | 1.58% | -62.0% | |
| PIRS | PIERIS PHARMACEUTICALS INC | $12,083,000 | -26.9% | 3,196,527 | 0.0% | 1.37% | -54.4% | |
| ARGX | ARGENX SEsponsored adr | $7,774,000 | +16.0% | 22,200 | 0.0% | 0.88% | -27.6% | |
| GMAB | GENMAB A/Ssponsored ads | $5,044,000 | -9.5% | 127,500 | 0.0% | 0.57% | -43.5% | |
| DRNA | Exit | DICERNA PHARMACEUTICALS INC | $0 | – | -2,456,595 | -100.0% | -9.00% | – |
| XBI | Exit | SPDR S&P BIOTECH ETF TRput | $0 | – | -1,000,000 | -100.0% | -22.83% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| PIERIS PHARMACEUTICALS INC | 20 | Q3 2023 | 7.1% |
| ARROWHEAD PHARMACEUTICALS INC | 18 | Q3 2023 | 22.1% |
| UNIQURE NV | 18 | Q1 2023 | 10.8% |
| SPERO THERAPEUTICS INC | 16 | Q3 2022 | 15.8% |
| REGENXBIO INC | 16 | Q3 2023 | 12.6% |
| BLUEPRINT MEDICINES CORP | 15 | Q3 2023 | 17.3% |
| ARGENX SE | 15 | Q3 2023 | 3.7% |
| SPDR S&P BIOTECH ETF TR | 14 | Q4 2022 | 52.1% |
| MERUS N V | 14 | Q3 2023 | 13.0% |
| GENMAB A/S | 13 | Q3 2023 | 3.9% |
View Aquilo Capital Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Magenta Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Spero Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Merus N.V. | February 14, 2020 | 814,505 | 2.8% |
| SYNLOGIC, INC.Sold out | February 14, 2020 | 0 | 0.0% |
View Aquilo Capital Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-03-18 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| 13F-HR | 2023-02-14 |
View Aquilo Capital Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.